LAIV Immuno

• Research type

  Research Study

• Full title

  A phase III/IV open-label study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, or in previous receipt of the AS03B adjuvanted H1N1 (2009) influenza vaccine (Pandemrix ™).

• IRAS ID

  138593

• Contact name

  Elizabeth Miller

• Contact email

  liz.miller@phe.gov.uk

• Sponsor organisation

  Public Health England

• Eudract number

  2013-003592-35

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  14/LO/0227

• Date of REC Opinion

  7 Apr 2014

• REC opinion

  Further Information Favourable Opinion